IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

@inproceedings{Emery2008IL6RI,
  title={IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial},
  author={P T J Emery and Edward Keystone and H P Tony and Alain Cantagrel and Ronald F. van Vollenhoven and Alejandra Sanchez and Emma Alecock and Joo-Hyun Lee and Joel Kremer},
  booktitle={Annals of the rheumatic diseases},
  year={2008}
}
OBJECTIVES The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy. METHODS 499 patients with inadequate response to one or more TNF antagonists were randomly assigned to receive 8 mg/kg or… CONTINUE READING